Streetbeat News

Stock Prices

A

In the last three months, 6 analysts have provided diverse ratings on Agilent Technologies (NYSE:A), with a shift towards more cautious views in the recent 30 days. The average 12-month price target for Agilent has increased to $136.67, up 8.9% from the previous $125.50. Analyst actions include both upgrades and downgrades, reflecting varied expectations for the company's performance. Agilent, a life sciences and diagnostics firm, shows strong financial health with a high net margin and ROE, despite a recent revenue decline of -8.71%.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 6:00 pm

BLK

Over the past 15 years, BlackRock (NYSE:BLK) has delivered an average annual return of 15.68%, outperforming the market by 1.45% annually. With a current market capitalization of $119.23 billion, an investment of $100 in BLK 15 years ago would be worth $843.19 today.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 6:00 pm

POOL

Over the past 5 years, Pool Corporation (NASDAQ:POOL) has outperformed the market with an annualized return of 19.54%, growing a $1000 investment to $2,448.60. The company currently holds a market capitalization of $15.16 billion.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 6:00 pm

SPY

Fed's Williams indicates that discussions about rate cuts are a positive sign of progress in reducing inflation. He suggests that the Fed is likely to cut rates later this year, emphasizing that data will guide the decision-making process.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 5:59 pm

BMBL

Bumble Inc. (NASDAQ:BMBL) reported lower than expected Q4 results, with a quarterly loss of 19 cents per share against an estimate of 12 cents, and sales of $273.64 million versus the expected $275.29 million. The company announced a workforce reduction of 350 roles and provided revenue forecasts for Q1 and the full year 2024, projecting 8% to 11% growth. Following the report, Bumble's shares fell 13.3%, and analysts from Keybanc, JP Morgan, Piper Sandler, and Morgan Stanley adjusted their price targets downwards.

Portfolio Pulse from Avi Kapoor

February 28, 2024 | 5:58 pm

ALGT

BA

Allegiant's President announced the company expects to receive around 12 aircraft from Boeing in 2024, down from the initial estimate of 24. To mitigate the impact of Boeing's delivery delays, Allegiant has reactivated some used Airbus A320 jets. The first Max jet delivery is anticipated in the coming months. Despite these delays, the President assures that Allegiant's capacity plans will not be significantly affected.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 5:53 pm

SPY

Fed's Williams stated that the economy and job market are strong, with imbalances decreasing. The current 3.7% unemployment rate is considered around the long-term level, indicating risks to the Fed's job and inflation mandates are moving into a better balance.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 5:51 pm

IMNM

VKTX

XBI

The biotech sector has seen significant growth in early 2024, with Viking Therapeutics, Inc. (VKTX) and Immunome, Inc. (IMNM) being notable movers. David Prince from T3 Trading Group highlighted the sector's potential for continued growth, driven by large biotech firms seeking new growth opportunities through mergers, acquisitions, and asset purchases. The SPDR S&P Biotech ETF (XBI) has also performed well, reflecting the sector's positive trend. Prince also mentioned the impact of lower interest rates as a future catalyst for the biotech industry.

Portfolio Pulse from Erica Kollmann

February 28, 2024 | 5:51 pm

DPZ

MCD

SBUX

UBER

YUM

Domino's Pizza Inc (NYSE:DPZ) reported a profit beat, driven by its 'emergency pizza' offer, leading to a stock jump, a 25% dividend hike, and a $1 billion buyback announcement. Despite facing backlash in the Middle East and Asia, similar to McDonald's (NYSE:MCD), Yum Brands (NYSE:YUM), and Starbucks (NASDAQ:SBUX), due to geopolitical tensions, Domino's saw a revenue rise of 0.8% to $1.40 billion in Q4. Its partnership with Uber Eats (NYSE:UBER) contributed to new customer acquisition and is expected to boost sales through 2024.

Portfolio Pulse from Upwallstreet

February 28, 2024 | 5:49 pm

PTN

Palatin Technologies announced that its PL9643 MELODY-1 Pivotal Phase 3 clinical trial for dry eye disease did not meet its primary or secondary endpoints, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 5:49 pm